BioCardia (BCDA) Registration Filing summary

Management team and governance

• CEO and President is Peter Altman, Ph.D., with David McClung as CFO, supported by a board including Andrew Blank, Jim Allen, Bill Facteau, Richard Krasno, Jay M. Moyes, and Simon Stertzer, M.D.

Underwriters and syndicate

• H.C. Wainwright & Co., LLC is the exclusive underwriter or placement agent for offerings, with compensation terms including a 7% cash fee on gross proceeds (reduced to 3.5% for certain investors), a 1% management fee, and specified expense allowances.

• The engagement includes a right of first refusal for Wainwright on future financings within six months of each offering and a tail provision for compensation on subsequent financings involving certain investors within 12 months post-engagement.

• The engagement period was extended multiple times, most recently to 30 days after September 3, 2025.

Offering details and pricing

• The offering may be structured as underwritten, best efforts, or private placement, with Wainwright's involvement on a reasonable best efforts basis and no guarantee of successful completion.

• Compensation and expense terms are increased for public offerings, with non-accountable expenses up to $50,000 and legal/out-of-pocket expenses up to $90,000.